Maplight Therapeutics (NASDAQ:MPLT) Director Buys $148,702.40 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Troy Cox acquired 15,620 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was bought at an average cost of $9.52 per share, for a total transaction of $148,702.40. Following the completion of the transaction, the director directly owned 15,620 shares of the company’s stock, valued at approximately $148,702.40. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Maplight Therapeutics Stock Performance

MPLT traded up $2.41 on Tuesday, reaching $12.31. The company had a trading volume of 5,538,981 shares, compared to its average volume of 904,055. The stock has a market cap of $524.65 million and a P/E ratio of -0.30. Maplight Therapeutics, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $40.43. The company’s fifty day moving average is $31.54 and its 200 day moving average is $25.00.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, sell-side analysts expect that Maplight Therapeutics, Inc. will post -5.13 EPS for the current year.

More Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: The ZEPHYR trial met its primary endpoint for the 210/3 mg twice-daily dose, which produced a statistically significant improvement in PANSS total score versus placebo. The dose also showed benefits on cognition, symptom severity and positive symptoms, with generally favorable tolerability. MapLight plans another potentially registrational trial and an FDA End-of-Phase 2 meeting. MapLight Announces Positive Topline Results
• Positive Sentiment: Analysts still see potential value after the selloff. HC Wainwright retained a “buy” rating with a $26 price target, while Morgan Stanley maintained “equal weight” with a $21 target—both above the recent trading level, although each firm reduced its target substantially. Analyst Rating Reports
• Neutral Sentiment: The twice-daily regimen’s success may preserve a development path for ML-007C-MA, but the results are not yet sufficient for approval. MapLight expects to conduct another trial to replicate the findings before pursuing registration.
• Negative Sentiment: The key disappointment was the once-daily dosing arm, which failed to show statistically significant symptom improvement. Investors viewed this as a major setback because a once-daily treatment could have offered a simpler, more convenient option. The news erased more than $1 billion in market value and sharply reduced confidence in the program. MapLight Once-Daily Trial Report
• Negative Sentiment: A law firm has announced an investor fraud investigation opportunity related to MapLight. The notice does not establish wrongdoing, but such announcements can add legal and reputational uncertainty to an already volatile stock. Investor Fraud Investigation Notice

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MPLT. Strs Ohio bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics during the fourth quarter worth $70,000. New York State Common Retirement Fund acquired a new position in Maplight Therapeutics in the fourth quarter valued at $93,000. MetLife Investment Management LLC bought a new stake in Maplight Therapeutics during the fourth quarter valued at $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics during the 4th quarter worth about $205,000.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Craig Hallum reiterated a “buy” rating and set a $25.00 price objective on shares of Maplight Therapeutics in a research report on Tuesday. Needham & Company LLC raised their price target on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maplight Therapeutics in a research note on Monday, July 13th. UBS Group boosted their price objective on shares of Maplight Therapeutics from $48.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Finally, Canaccord Genuity Group decreased their target price on shares of Maplight Therapeutics from $43.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday. Four analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $34.42.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.